Education
About Us
Working with TipRanks
Follow Us
Damora Therapeutics (DMRA)
NASDAQ:DMRA
Total Valuation
Damora Therapeutics has a market cap or net worth of $1.45B. The enterprise value is $1.44B.
Market Cap$1.45B
Enterprise Value$1.44B
Share Statistics
Damora Therapeutics has 60,240,070 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,240,070
Owned by Insiders16.09%
Owned by Institutions0.23%
Financial Efficiency
Damora Therapeutics’s return on equity (ROE) is -1.48 and return on invested capital (ROIC) is -105.96%.
Return on Equity (ROE)-1.48
Return on Assets (ROA)-1.25
Return on Invested Capital (ROIC)-105.96%
Return on Capital Employed (ROCE)-1.06
Revenue Per Employee0.00
Profits Per Employee-4.29M
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Damora Therapeutics is ―. Damora Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio1.74
Price to Fair Value1.74
Price to FCF-1.35
Price to Operating Cash Flow0.00
PEG Ratio0.02
Income Statement
In the last 12 months, Damora Therapeutics had revenue of 0.00 and earned -21.44M in profits. Earnings per share was -18.53.
Revenue0.00
Gross Profit-181.00K
Operating Income-16.90M
Pretax Income-21.40M
Net Income-21.44M
EBITDA-16.72M
Earnings Per Share (EPS)-18.53
Cash Flow
In the last 12 months, operating cash flow was -29.96M and capital expenditures 0.00, giving a free cash flow of -29.96M billion.
Operating Cash Flow-29.96M
Free Cash Flow-29.96M
Free Cash Flow per Share-0.50
Dividends & Yields
Damora Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.28
52-Week Price Change467.61%
50-Day Moving Average26.29
200-Day Moving Average13.68
Relative Strength Index (RSI)39.42
Average Volume (3m)5.26M
Important Dates
Damora Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Damora Therapeutics as a current ratio of 14.07, with Debt / Equity ratio of 21.20%
Current Ratio14.07
Quick Ratio14.07
Debt to Market Cap0.05
Net Debt to EBITDA0.76
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Damora Therapeutics has paid 41.00K in taxes.
Income Tax41.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Damora Therapeutics EV to EBITDA ratio is -0.75, with an EV/FCF ratio of -0.67.
EV to Sales0.00
EV to EBITDA-0.75
EV to Free Cash Flow-0.67
EV to Operating Cash Flow-0.67
Balance Sheet
Damora Therapeutics has $22.86M in cash and marketable securities with $77.00K in debt, giving a net cash position of $22.79M billion.
Cash & Marketable Securities$22.86M
Total Debt$77.00K
Net Cash$22.79M
Net Cash Per Share$0.38
Tangible Book Value Per Share$12.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Damora Therapeutics is $44.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$44.00
Price Target Upside83.26% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast37.42%